Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of AGuIX Nanoparticles and Temozolomide with Radiotherapy for Patients with Newly Diagnosed Glioblastoma

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of brain cancer called glioblastoma, which is a fast-growing and aggressive form of cancer that occurs in the brain. The study is testing a new treatment that combines a special type of nanoparticles called AGuIX with standard treatments like radiotherapy and a chemotherapy drug called Temozolomide (TMZ). The AGuIX nanoparticles are designed to enhance the effects of radiotherapy, potentially improving treatment outcomes for patients with newly diagnosed glioblastoma.

The purpose of the study is to find the best dose of AGuIX when used with radiotherapy and Temozolomide, and to see how effective this combination is in treating glioblastoma. The study is divided into two phases. In the first phase, researchers will determine the safest and most effective dose of AGuIX. In the second phase, they will evaluate how well the treatment works by looking at how long patients live without the cancer getting worse over a period of six months. Some participants will receive a placebo instead of AGuIX to compare the results.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also monitor the overall survival of participants, their response to the treatment, and any side effects they may experience. Additionally, the study will assess the distribution of the nanoparticles in the body and their impact on the tumor environment. The trial is expected to continue until 2027, with ongoing assessments to ensure the safety and effectiveness of the treatment.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    The study begins with the administration of AGuIX nanoparticles through an intravenous infusion. This is a solution that is given directly into the bloodstream.

    The purpose of this phase is to determine the recommended dose of AGuIX when used with radiotherapy and Temozolomide (TMZ), a medication taken orally to treat brain tumors.

    During this phase, the focus is on identifying any side effects and determining the highest dose that can be given safely.

  2. Step 2

    Concomitant radiochemotherapy period

    This phase involves the combination of radiotherapy and Temozolomide with the recommended dose of AGuIX.

    The treatment aims to assess the effectiveness of this combination in controlling the tumor.

    The primary goal is to measure the progression-free survival rate at six months, which indicates how long the disease does not worsen.

  3. Step 3

    Monitoring and assessment

    Throughout the study, regular assessments are conducted to monitor the safety and effectiveness of the treatment.

    These assessments include measuring the distribution of nanoparticles in the body, overall survival rates, and neurological status using clinical evaluations and questionnaires.

    The intake of corticosteroids, which are medications used to reduce inflammation, is also evaluated.

  4. Step 4

    Follow-up period

    After completing the treatment phases, there is a follow-up period to continue monitoring the patient's health and any long-term effects of the treatment.

    The study aims to assess the overall survival rate at six and twelve months after the start of treatment.

    The safety profile of AGuIX nanoparticles in combination with radiotherapy and TMZ is evaluated throughout the study.

Who can join the trial?

15 criteria

  • Must have a confirmed diagnosis of **grade IV glioblastoma**, which is a type of brain cancer, through a biopsy or partial surgery.
  • If taking **corticosteroids** (a type of medication), the dose must be stable or decreasing for at least 14 days before joining the study.
  • Must be able to swallow and keep down oral medication.
  • Women must have a negative pregnancy test within 7 days before starting the treatment.
  • Women who can have children and men with partners who can have children must agree to use an approved method of **contraception** during the study and for at least 6 months after the last treatment.
  • Must provide signed informed consent, which means agreeing to participate after understanding the study details.
  • Must be part of a social security system.
  • Must not have had surgery or only had partial removal of the tumor.
  • Must have a **Karnofsky Performance Status (KPS)** of 70% or higher, which measures the ability to perform daily activities.
  • Must be between 18 and 74 years old.
  • Must have a life expectancy of at least 6 months.
  • Must have a **platelet count** of at least 100,000 per cubic millimeter, which is important for blood clotting.
  • Must have **hemoglobin (Hb)** levels of at least 10 grams per liter, which is important for carrying oxygen in the blood.
  • Must have **creatinine** levels less than 1.5 times the upper normal limit or a **creatinine clearance** of at least 50 milliliters per minute, which indicates kidney function.
  • Must have **liver function** tests within certain limits: **GGT, PAL, ASAT, ALAT** less than 3 times the upper normal limit, and **bilirubin** less than 1.5 times the upper normal limit.

Who cannot join the trial?

3 criteria

  • Patients who have not been newly diagnosed with **glioblastoma**. Glioblastoma is a type of brain cancer.
  • Patients who are not within the specified age range for the study.
  • Patients who are part of a vulnerable population, which means they may need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • AGuIX

    is a type of nanoparticle being studied for its potential to enhance the effects of radiotherapy. In this trial, it is used in combination with radiotherapy to treat newly diagnosed glioblastoma, a type of brain cancer. The goal is to determine the best dose of AGuIX to use with radiotherapy and to see how effective this combination is in stopping the cancer from progressing.

  • Temozolomide

    is a chemotherapy drug that is often used to treat brain tumors like glioblastoma. In this trial, it is given alongside radiotherapy and AGuIX to see if the combination can improve treatment outcomes. Temozolomide works by damaging the DNA of cancer cells, which can help to stop their growth and spread.

What is already known about the treatment

  • Temozolomide

    This medication is administered orally in the form of capsules. It is currently well-established in medical practice and literature, particularly for treating certain types of brain tumors. The main therapeutic indication for Temozolomide is the treatment of newly diagnosed glioblastoma, often in combination with radiotherapy. At the molecular level, Temozolomide works by damaging the DNA of cancer cells, which prevents them from dividing and growing. It is classified as an alkylating agent, a type of chemotherapy drug.

  • AGuIX Nanoparticles

    These are administered intravenously and are currently being studied in clinical trials. They are not yet widely used in standard medical practice but show promise in enhancing the effects of radiotherapy. The main therapeutic indication being explored is their use in combination with radiotherapy and Temozolomide for newly diagnosed glioblastoma. AGuIX nanoparticles work by increasing the absorption of radiation in tumor cells, thereby enhancing the effectiveness of radiotherapy. They are classified as radiosensitizers, which are substances that make cancer cells more sensitive to radiation therapy.

Investigated diseases

Glioblastoma – Glioblastoma is a type of brain cancer that originates from glial cells, which support nerve cells in the brain. It is known for its aggressive nature and rapid growth, often infiltrating surrounding brain tissue. Symptoms can include headaches, seizures, and neurological deficits such as weakness or speech difficulties, depending on the tumor's location. As the disease progresses, these symptoms may worsen, and new symptoms can develop. Glioblastoma is typically diagnosed through imaging studies and biopsy. It is considered one of the most challenging brain tumors to treat due to its complex and invasive growth patterns.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-517114-15-00Protocol codeNANO-GBMEstimated enrolment66 patientsSponsorCentre Jean Perrin

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.